Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2025 07:00 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...
November 05, 2025 16:01 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other...
November 04, 2025 08:00 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Participate in Four Investor Conferences During November

NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...
October 29, 2025 15:30 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase...
October 16, 2025 07:00 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell...
October 02, 2025 08:00 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

NEW YORK and WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
September 11, 2025 16:07 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
September 09, 2025 22:35 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
September 08, 2025 16:00 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
September 08, 2025 07:00 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative...